Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.38 |
| ▸ | ATR | Q13535 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.35 |
| ▸ | APLNR | P35414 | 1/20 | 0.35 |
| ▸ | STK17B | O94768 | 1/20 | 0.34 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18805591 | 0.84 | ATR (0.45) | NPC1AAK1ATRL3MBTL1MAP4K4 | |
| SCHEMBL29400652 | 0.84 | ATR (0.45) | NPC1AAK1ATRL3MBTL1MAP4K4 | |
| SCHEMBL21177638 | 0.84 | GAA (0.42) | GAANPC1MEN1KMT2ARAB9A | |
| SCHEMBL12705675 | 0.81 | GAA (0.40) | GAANPC1MEN1KMT2ARAB9A | |
| SCHEMBL2227738 | 0.80 | KMO (0.48) | AAK1 | |
| SCHEMBL14692716 | 0.79 | GAA (0.46) | GAANPC1MEN1KMT2ARAB9A | |
| SCHEMBL23852050 | 0.79 | GAA (0.46) | GAANPC1MEN1KMT2ARAB9A | |
| SCHEMBL27775454 | 0.78 | GAA (0.45) | GAANPC1MEN1KMT2ARAB9A | |
| SCHEMBL11909033 | 0.77 | STK17B (0.47) | GAAMEN1KMT2AALDH1A1STK17B | |
| SCHEMBL21177599 | 0.77 | KMT2A (0.41) | GAANPC1MEN1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019141957-A1 | N-PYRIMIDINYL HYDROXY PYRAZOLE DERIVATIVES AND USES THEREOF | CADO BIOTECHNOLOGY IVS (DK) | 2019-07-25 | — | — | WO | disclosed |
| US-10301289-B2 | Method for the preparation of triazole compounds | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-05-28 | — | — | US | disclosed |
| US-20150087827-A1 | METHOD FOR THE PREPARATION OF TRIAZOLE COMPOUNDS | BAYER PHARMA AKTIENGESELLSCAFT (DE) | 2015-03-26 | — | — | US | disclosed |
| US-20150087827-A1 | METHOD FOR THE PREPARATION OF TRIAZOLE COMPOUNDS | BAYER PHARMA AKTIENGESELLSCAFT (DE) | 2015-03-26 | — | — | US | disclosed |
| US-7919528-B2 | Antibiotic; bactericides | GLAXOSMITHKLINE LLC (US) | 2011-04-05 | — | — | US | disclosed |
| US-7919528-B2 | Antibiotic; bactericides | GLAXOSMITHKLINE LLC (US) | 2011-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10301289-B2 | Method for the preparation of triazole compounds | CYP4B1, BRI3BP, BRD4 | GAA 2871/4885NPC1 4010/4885MEN1 819/4885 |
| US-20150087827-A1 | METHOD FOR THE PREPARATION OF TRIAZOLE COMPOUNDS | CYP4B1, BRI3BP, BRD4 | GAA 2871/4885NPC1 4010/4885MEN1 819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.